heart failure
147 all articles · 20 / page
Latest news
Tag
Biomarker, Functional Status, and Quality-of-Life Trajectories Before Modes of Death in Heart Failure: Post Hoc Analysis of the FINEARTS-HF Randomized Clinical Trial
This study reveals that sudden death in heart failure patients often follows gradual clinical decline, challenging the notion that such deaths are always abrupt.
Exploring the Impact of Body Mass Index on Heart Failure Outcomes: Insights from Mendelian Randomization
This study leverages Mendelian randomization to demonstrate that genetically elevated BMI is associated with increased mortality and adverse cardiovascular outcomes in heart failure, irrespective of ejection fraction status, underscoring po
Body Mass Index, Clinical Outcomes, and Mortality in Heart Failure: A Mendelian Randomization Study
This study uses Mendelian randomization to show that higher genetically predicted BMI is associated with increased all-cause mortality and cardiovascular events in heart failure patients, regardless of ejection fraction status.
Arrhythmia Burden and Clinical Responses Under Continuous Monitoring in Heart Failure: Observations From the ALLEVIATE-HF Trial
Continuous monitoring in heart failure patients revealed a high burden of arrhythmias linked to more interventions, hospitalizations, and heart failure events, but not altered by the study’s congestion-management strategy.
Arrhythmia Burden and Clinical Responses Under Continuous Monitoring in Heart Failure: Observations From the ALLEVIATE-HF Trial
Continuous ICM monitoring in heart failure uncovered a high arrhythmia burden, including atrial fibrillation, bradyarrhythmia, and VT/VF, which was linked to more interventions, hospitalizations, and heart failure events.
Risk-Based Nurse-Managed Personalized Heart Failure Interventions: The ALLEVIATE-HF Trial
The ALLEVIATE-HF trial found that implantable monitor-based risk alerts with nurse-managed diuretic treatment were safe but did not significantly improve the main heart failure outcome composite.
Arrhythmia Burden and Clinical Responses Under Continuous Monitoring in Heart Failure: Findings from the ALLEVIATE-HF Trial
Continuous implantable monitoring in heart failure revealed a high burden of arrhythmias, strongly linked to hospitalizations and treatment changes, but not reduced by protocol-directed congestion management.
Food Delivery After Heart Failure Hospitalization Was Feasible but Did Not Reduce 90-Day HF Readmissions
A randomized trial found that medically tailored meals and fresh produce were highly feasible after HF hospitalization, but neither strategy improved the primary 90-day heart failure utilization outcome versus usual care.
Role of Atrial Pacing Support in Cardiac Resynchronization Therapy: A Noninferiority Randomized Trial
A randomized trial found that a two-lead CRT-D system without atrial pacing was noninferior to standard three-lead CRT-D in selected heart failure patients, with fewer atrial lead-related complications.
Arrhythmia Burden and Clinical Responses Under Continuous Monitoring in Heart Failure: Observations From the ALLEVIATE-HF Trial
Continuous ICM monitoring in heart failure found a high burden of atrial fibrillation, bradyarrhythmia, and VT/VF. Arrhythmias were linked to more interventions and higher hospitalization risk, but the congestion-management strategy did not
Pulmonary Artery Pressure Falls After ARNI and MRA Initiation, but Not SGLT2 Inhibitors, in Hemodynamically Monitored Heart Failure: Insights From GUIDE-HF
In a GUIDE-HF analysis using CardioMEMS, new ARNI and MRA initiation was associated with modest short-term reductions in diastolic pulmonary artery pressure, whereas SGLT2 inhibitor initiation showed no detectable pressure change and β-bloc
Implantable Monitor–Guided, Nurse-Led Diuretic Escalation Was Safe but Did Not Improve Outcomes in ALLEVIATE-HF
In ALLEVIATE-HF, ICM-based high-risk detection linked to centralized nurse-managed diuretic intervention was safe, but did not significantly improve the hierarchical composite outcome versus observation.
SREBP1 Activation of NHE3 Weakens Heart Contraction and Worsens Heart Failure
Researchers found that SREBP1 directly activates NHE3 in failing hearts, causing sodium and calcium overload, weaker cardiac contraction, and worse heart failure. The findings reveal a new mechanism in HFrEF and suggest a potential therapeu
Outcomes of Heart Failure With Reduced, Mildly Reduced, or Preserved Ejection Fraction: ESC HF III Registry
The ESC HF III Registry found substantial mortality and rehospitalization across heart failure phenotypes. Risk was highest after acute hospitalization and generally worse with reduced ejection fraction, but HFmrEF and HFpEF also carried si
Heart Failure Medication Adherence Depends Less on Motivation Than on Whether Treatment Fits Daily Life
A qualitative study in heart failure shows that medication adherence is shaped by regimen complexity, diuretic burden, psychosocial stressors, cost, and care coordination rather than motivation alone.
Tricuspid Valve Replacement Outcomes by Baseline Tricuspid Regurgitation Severity: TRISCEND II Trial
TRISCEND II showed that transcatheter tricuspid valve replacement with EVOQUE markedly reduced tricuspid regurgitation and improved clinical outcomes across baseline severity levels, with a stronger signal for benefit in massive or torrenti
Subclinical Hyperthyroidism Carries Measurable Risks of Atrial Fibrillation, Heart Failure, and Death in Primary Care
A large Dutch primary care cohort links subclinical hyperthyroidism to higher risks of atrial fibrillation, heart failure, and all-cause mortality, with particularly notable relative risks in younger adults and in patients with more strongl
GLP-1 Receptor Agonists Show Lower Heart Failure Risk Versus DPP-4 Inhibitors in Type 2 Diabetes
New research comparing diabetes medications reveals GLP-1 receptor agonists lower heart failure hospitalization risk compared to DPP-4 inhibitors, while showing similar risk to SGLT-2 inhibitors in type 2 diabetes patients.
ATTR-CM Is Often Diagnosed Years After Heart Failure in Medicare Patients
In Medicare beneficiaries, ATTR-CM was diagnosed a median 494 days after heart failure and 840 days after loop diuretic initiation, with delays more common in women and patients with several common comorbidities.